Related Experiment Video
Updated: Jul 16, 2026
07:59
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Long-circulating liposomes radiolabeled with [18F]fluorodipalmitin ([18F]FDP).
Jan Marik1, Michaelann S Tartis, Hua Zhang
1Department of Biomedical Engineering, University of California Davis, Davis, CA 95616, USA.
Nuclear Medicine and Biology
|February 20, 2007
Summary
Researchers synthesized a novel radiolabeled diglyceride, [18F]fluorodipalmitin ([18F]FDP), for labeling long-circulating liposomes. This new reagent demonstrates potential for advanced imaging applications and drug delivery systems.
Area of Science:
- Radiochemistry
- Nanomedicine
- Biomedical Imaging
Background:
- Developing effective radiolabeling agents is crucial for advancing molecular imaging and targeted drug delivery.
- Liposomes are promising drug carriers, but efficient and stable radiolabeling methods are needed.
Purpose of the Study:
- To synthesize a novel radiolabeled diglyceride, [18F]fluorodipalmitin ([18F]FDP).
- To evaluate the potential of [18F]FDP for radiolabeling long-circulating liposomes for PET imaging.
Main Methods:
- Synthesis of [18F]FDP via nucleophilic substitution.
- Preparation of radiolabeled polyethylene glycol-coated liposomes incorporating [18F]FDP.
- PET imaging and biodistribution studies of free and liposome-incorporated [18F]FDP.
Main Results:
- [18F]FDP was synthesized with a decay-corrected yield of 43+/-10%.
- Radiolabeled liposomes were prepared with a decay-corrected yield of 70+/-8%.
- Liposomal [18F]FDP exhibited prolonged circulation in blood (90 min) compared to free [18F]FDP, which showed high uptake in liver, spleen, and lungs.
Conclusions:
- [18F]FDP is a viable reagent for radiolabeling lipid-based drug carriers.
- The developed method allows for the creation of stable, long-circulating radiolabeled liposomes.
- This technique holds potential for various applications in drug delivery and PET imaging.
